|Bid||0.00 x 1000|
|Ask||0.00 x 1800|
|Day's Range||234.06 - 237.24|
|52 Week Range||166.30 - 237.24|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||18.15|
|Earnings Date||Jan 27, 2020 - Jan 31, 2020|
|Forward Dividend & Yield||5.80 (2.48%)|
|1y Target Est||226.18|
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).
Amgen Inc. said late Wednesday its board hiked the quarterly dividend by 10%. The biotech drug maker said its board declared a dividend of $1.60 a share, up from its previous dividend of $1.45 a share, to be paid on March 6 to shareholders of record as of Feb. 14. Shares of Amgen were down less than 0.1% after hours, following a less than 0.1% rise to finish the session at $234.01.
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020. The dividend will be paid on March 6, 2020, to all stockholders of record as of the close of business on Feb. 14, 2020. This represents a 10% increase from that paid in each of the previous four quarters. Since the Company initiated a dividend in 2011, it has increased the dividend each year with the quarterly payout in 2019 up more than five-fold since its inception.
Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.
Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. The data will be presented in a late-breaking abstract session at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.
Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of the role and public health impact of Lipoprotein(a) as a risk factor for cardiovascular disease. The study appears today in the online edition of the Journal of the American College of Cardiology.
The biotech company acquired its first Bay Area presence 15 years ago; now it's planning to move into a high-profile biotech-focused project.
Amgen (NASDAQ:AMGN) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific campus development in South San Francisco. The new location, currently under construction at Oyster Point, will house Amgen's Bay Area employees focused on cardiometabolic, inflammation and oncology, research.
Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab): for the treatment of moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe Crohn's Disease (CD) in the adult and pediatric population, moderate-to-severe ulcerative colitis (UC) in the adult and pediatric population, chronic severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website. The biosimilar, Avsola, has the same chemical components, dosage form and strength as Remicade and would treat a range of autoimmune disorders. Amgen did not give the pricing of the drug immediately, but said is confident to compete in the biosimilar market.
PiperJaffrey analyst Christopher Raymond wrote that health-care/biotech-focused funds saw a second week of inflows as stocks including Biogen and Amgen are having great fourth quarters.
Shares of Amgen are on an upswing after the company won a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
"This is a much better company than it was just six months ago," said Jim Cramer. In this daily bar chart of AMGN, below, we can see a wide base pattern from last December to the end of October. The On-Balance-Volume (OBV) line has been leading the way higher since May and confirms the price strength with its signs of aggressive buying.
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months. Pharmacy benefits managers like Abarca act as middlemen in the drug supply chain, and negotiate discounts on drugs on behalf of health insurers. Depending on the discounts drugmakers are willing to provide, pharmacy benefits managers make decisions about which drugs to include in coverage plans.
Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Biogen Inc (NASDAQ: BIIB ). He is concerned about the stock because a Baird analyst expressed his skepticism about Biogen's Alzheimer's ...